BioSpace News Archive

Boston Heart Diagnostics, part of the Eurofins network of companies, announces the launch of LipidSeq™, a revolutionary genetic test for cardiovascular disease.

Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO.

Latest Study on “Bioanalytical Testing Services Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Latest Study on “Biobanking Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Eargo, Inc., a medical device company on a mission to improve hearing health, announced its support of the new regulatory category of over-the-counter hearing aids, as finalized by the Food and Drug Administration Wednesday, August 17, 2022.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Wednesday, August 24, 2022.

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.

The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 180.09 Billion by 2028, according to a new report by Reports and Data.

According to the current analysis of Reports and Data, the global Sacral neuromodulation market was valued at USD 2,432.9 Million in 2020 and is expected to reach USD 3,498.2 Million by year 2028, at a CAGR of 4.94 %.